Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

3q27 rearrangements (BCL6) in non Hodgkin lymphoma

t(3;Var)(q27;Var) in non Hodgkin lymphoma

Written2000-07Antonio Cuneo, Jean-Loup Huret
Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 2081
Note
  • 3q27 rearrangements occur in distinct clinicopathological entities of B-cell non Hodgkin lymphoma (NHL), including diffuse large cell lymphoma (DLCL), follicle centre cell lymphoma (FCCL) and marginal zone B-cell lymphoma (MZBCL) in the REAL classification; very rare cases were also reported with mantle cell lymphoma and chronic lymphocytic leukemia
  • 3q27 breaks are usually, but not invariably, associated with rearrangements of the BCL6 gene located at the 3q27 chromosome band; likewise rearrangements of this gene may occur without detectable 3q27 breaks
  •  
      t(3;22)(q27;q11) - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at theWaisman Center

    Clinics and Pathology

    Disease Diffuse large cell lymphoma (DLCL)
    Note this biologically heterogeneous group of lymphomas in the REAL proposal accounts for as many as 40% of NHL in western countries and includes the entities of centroblastic lymphoma, immunoblastic lymphoma and B-cell anaplastic lymphoma recognized by the Kiel classification
    Phenotype / cell stem origin the cell of origin is probably a large transformed B-cell, frequently deriving from the follicle centre, harbouring somatic hypermutation of the Ig genes and ongoing mutations (antigen driven stimulation). The phenotype is usually CD19+, CD22+, CD10-/+, SIg+
    Epidemiology 10-20% of DLCL carry 3q27 translocations detectable at banding analysis, appoximately 50% of which may be expected to be associated with BCL6 rearrangement; molecular genetic methods proved very efficient in demonstrating this genetic lesion and studies using southern blotting detecting BCL6 breaks in the 4.0 kb major breakpoint region showed 20-30% of unselected DLCL to be rearranged
    Pathology there is no distinctive histological features in DLCL with 3q27/BCL6 rearrangement as compared with other DLCL; the proliferation consists of a diffuse infiltrate of large cells with vescicular nuclei and prominent nucleoli with basophilic cytoplasm; criteria for distinguishing those cases with a predominance of immunoblasts or of anaplastic B-cells were put forward but were felt not to be enough reproducible as to allow for proper categorization of distinct pathological entities; 3q27 abnormalities were seen in similar frequency in the immunoblastic variant and in the centroblastic variant of DLCL in a study
    Prognosis a predominance of extra-nodal forms and a relatively favourable outcome was observed in BCL6-rearranged DLCL but BCL6 failed as a prognostic indicator when compared to other molecular genetic lesions; thus, the assessment of the prognostic significance of 3q27 or BCL6 breaks in DLCL needs further investigation in prospective studies

    Disease Follicle centre cell lymphoma (FCCL)
    Note FCCL accounts for approximately 30-40% of all NHL in western countries
    Phenotype / cell stem origin the neoplasia derives from centrocytes / centroblasts unable to progress through the germinal centre, carrying somatic hypermutation of the IgV genes and a pan-B+, CD10+/-, CD5-, sIg+ phenotype
    Epidemiology 3q27 translocations involving the chromosome regions where Ig genes are located (2p11: IgK, 14q32: IgH, 22q11: IgL) were detected in 6.5% of FCCL; a 16% incidence for any 3q27 break was reported; the association of 3q27/BCL6 involvement with the classical t(14;18) was described; molecular genetic studies found a 6-14% incidence for BCL6 rearrangement in FCCL
    Prognosis no specific correlation was established between 3q27 breaks and specific clinicopathological features of FCCL

    Disease Marginal zone B-cell lymphoma (MZBCL)
    Note 7-8% of NHL show the clinicopathological features of MZBCL
    Phenotype / cell stem origin the transformed cells derive form marginal zone lymphocytes harbouring hypermutated IgV genes with the following phenotype: pan-B+, CD5-/+, CD10-, CD23-, CD11c+/-, cyIg +(40% of the cells), sIgM+ bright, sIgD-
    Epidemiology a minority of MZBCL may carry a 3q27/BCL6 translocation, mostly t(3;14)(q27;q32)
    Clinics there is no distinctive clinicopathological feature in this cytogenetic subset of MZBCL, but a predominance of extra-nodal forms over splenic and nodal types and an excess of large blast-like cells were noted

    Genetics

    below are listed translocations involving -or likely to involve- BCL6 in 3q27, and a partner gene in the other breakpoint

    Cytogenetics

    Cytogenetics Morphological
  • t(2;3)(p12;q27): the gene in 2p12 is IgK
  • t(3;3)(q27;q29): the gene in 3q29 is TFRC, the transferrin receptor
  • t(3;4)(q27;p13): the gene in 4p13 is RHOH, a GTPase of the Ras superfamily; role in signal transduction
  • t(3;6)(q27;p22): the gene in 6p22 is histone H1F1, an architectural protein with a role in chromatin condensation and in gene regulation
  • t(3;6)(q27;p21.2): the gene in 6p21.2 is PIM-1, a protein kinase
  • t(3;7)(q27;p12): the gene in 7p12 is ZNFN1A1/Ikaros, a Zn finger protein involved in cell differentiation
  • t(3;8)(q27;q24)
  • t(3;11)(q27;q23): the gene in 11q23 is OBF1, a B-cell specific transcriptional coactivator
  • t(3;13)(q27;q14): the gene in 13q14 is LCP1/L-plastin, a gene which belongs to an actin-binding protein family
  • t(3;14)(q27;q32): the gene in 14q32 is IgH
  • t(3;15)(q27;q22)
  • t(3;16)(q27;p13): the gene in 16p13 is MHC2TA/CIITA, a Class II histocompatibility complex transactivator
  • t(3;17)(q27;q11)
  • t(3;18)(q27;p11.2): the gene in 18p11.2 is EIF4A2, a DEAD box helicase
  • t(3;22)(q27;q11): the gene in 22q11 is IgL
  • t(3;?)(q27;?): the gene is HSP89A, a member of the HSP90 sub-family of the heat-shock protein (HSP) family.
  • finally, breakpoints in 1p34, 1p32, 2q21, 3p14, 6q23, 12p13, 14q11, 16p11.2,and 16p13 have also been described
  • however, cases of apparently simple translocations involving 3q27 -but not 14q32- (e.g. t(1;3)(q21;q37), or t((3;6)(q27;p25)) have disclosed insertion of IgH sequences within the 3q27 breakpoint
  • moreover, in a substantial percentage of cases, a breakpoint in 3q27 in NHL is accompanied with germline BCL6: another gene is likely to be implicated in these cases (or else, the rearranged sequence, although distant, still disregulates BCL6)
  • Cytogenetics Molecular 3q27 anomalies are often associated with well known primary anomalies such as t(8;14)(q24;q32), t(11;14)(q13;q32), t(14,18)(q32;q21)

    Genes involved and Proteins

    Gene NameBCL6 (B-Cell Lymphoma 6)
    Location 3q27.3
    Note BCL6 mutations are regarded as a genetic marker of B-cell transition through the germinal center
    Dna / Rna 10 exons; alternative splicing of exons 1 (1a and 1b), without modification of the open reading frame
    Protein transcription factor; belongs to the Krüppel family, with a N-term BTB/POZ domain and 6 zinc fingers; transcription repressor

    Result of the chromosomal anomaly

    Hybrid gene
    Note the translocation partners of BCL6 are not confined to the immunoglobulin superfamily, contrarily to the situation found with c-MYC, BCL1, or BCL2
    Description breakpoint in the first non-coding exon (containing the 2 promoters) or the first intron of BCL6; the partner gene therefore fuses with the second exon of BCL6, resulting in a 5' partner - 3' BCL6 fusion transcript; it is supposed that substitution of the promoter of BCL6 may be responsible for BCL6 regulation, or that a break in the breakpoint cluster region of BCL6 may inhibit a sequence involved in BCL6 regulation; partners other than immunoglobulin lack homology with switch regions, VDJ sequences, or Chi sequences
      
    Fusion Protein
    Description no fusion protein; the 5' regulatory region of BCL6 is replaced by the 5' regulatory region of the partner gene.
      

    Bibliography

    A recurring translocation, t(3;6)(q27;p21), in non-Hodgkin's lymphoma results in replacement of the 5' regulatory region of BCL6 with a novel H4 histone gene.
    Akasaka T, Miura I, Takahashi N, Akasaka H, Yonetani N, Ohno H, Fukuhara S, Okuma M
    Cancer research. 1997 ; 57 (1) : 7-12.
    PMID 8988030
     
    Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.
    Baron BW, Nucifora G, McCabe N, Espinosa R 3rd, Le Beau MM, McKeithan TW
    Proceedings of the National Academy of Sciences of the United States of America. 1993 ; 90 (11) : 5262-5266.
    PMID 8506375
     
    LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
    Bastard C, Deweindt C, Kerckaert JP, Lenormand B, Rossi A, Pezzella F, Fruchart C, Duval C, Monconduit M, Tilly H
    Blood. 1994 ; 83 (9) : 2423-2427.
    PMID 8167331
     
    Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27.
    Chaganti SR, Rao PH, Chen W, Dyomin V, Jhanwar SC, Parsa NZ, Dalla-Favera R, Chaganti RS
    Genes, chromosomes & cancer. 1998 ; 23 (4) : 328-336.
    PMID 9824206
     
    Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases.
    Cuneo A, Bigoni R, Roberti MG, Milani R, Agostini P, Cavazzini F, Minotto C, De Angeli C, Bardi A, Tammiso E, Negrini M, Cavazzini P, Castoldi G
    Haematologica. 2001 ; 86 (1) : 64-70.
    PMID 11146573
     
    TTF, a gene encoding a novel small G protein, fuses to the lymphoma-associated LAZ3 gene by t(3;4) chromosomal translocation.
    Dallery E, Galiègue-Zouitina S, Collyn-d'Hooghe M, Quief S, Denis C, Hildebrand MP, Lantoine D, Deweindt C, Tilly H, Bastard C
    Oncogene. 1995 ; 10 (11) : 2171-2178.
    PMID 7784061
     
    Four cases of follicular lymphoma with t(14;18)(q32;q21) and t(3;4)(q27;p13) with LAZ3 (BCL6) rearrangement.
    Daudignon A, Bisiau H, Le Baron F, Laï JL, Wetterwald M, Galiègue-Zouitina S, Morel P, Duthilleul P
    Cancer genetics and cytogenetics. 1999 ; 111 (2) : 157-160.
    PMID 10347555
     
    BCL6 gene rearrangements also occur in marginal zone B-cell lymphoma.
    Dierlamm J, Pittaluga S, Stul M, Wlodarska I, Michaux L, Thomas J, Verhoef G, Verhest A, Depardieu C, Cassiman JJ, Hagemeijer A, De Wolf-Peeters C, Van den Berghe H
    British journal of haematology. 1997 ; 98 (3) : 719-725.
    PMID 9332330
     
    Nonrandom fusion of L-plastin(LCP1) and LAZ3(BCL6) genes by t(3;13)(q27;q14) chromosome translocation in two cases of B-cell non-Hodgkin lymphoma.
    Galiègue-Zouitina S, Quief S, Hildebrand MP, Denis C, Detourmignies L, Laï JL, Kerckaert JP
    Genes, chromosomes & cancer. 1999 ; 26 (2) : 97-105.
    PMID 10469447
     
    The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma.
    Hosokawa Y, Maeda Y, Ichinohasama R, Miura I, Taniwaki M, Seto M
    Blood. 2000 ; 95 (8) : 2719-2721.
    PMID 10753856
     
    Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM
    Blood. 1998 ; 92 (9) : 3152-3162.
    PMID 9787151
     
    Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases.
    Maes M, Depardieu C, Dargent JL, Hermans M, Verhaeghe JL, Delabie J, Pittaluga S, Troufléau P, Verhest A, De Wolf-Peeters C
    Journal of hepatology. 1997 ; 27 (5) : 922-927.
    PMID 9382982
     
    A new non-random chromosomal translocation t(3;6)(q27;p21.3) associated with BCL6 rearrangement in two patients with non-Hodgkin's lymphoma.
    Miura I, Ohshima A, Takahashi N, Hashimoto K, Nimura T, Utsumi S, Saito M, Miki T, Hirosawa S, Miura AB
    International journal of hematology. 1996 ; 64 (3-4) : 249-256.
    PMID 8923787
     
    Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.
    Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A
    The New England journal of medicine. 1994 ; 331 (2) : 74-80.
    PMID 8208268
     
    Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms.
    Ohno H, Fukuhara S
    Leukemia & lymphoma. 1997 ; 27 (1-2) : 53-63.
    PMID 9373196
     
    Research of complementary/alternative medicine therapies in oncology: promising but challenging.
    Richardson MA
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 ; 17 (11 Suppl) : 38-43.
    PMID 10630261
     
    Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group.
    Schlegelberger B, Zwingers T, Harder L, Nowotny H, Siebert R, Vesely M, Bartels H, Sonnen R, Hopfinger G, Nader A, Ott G, Müller-Hermelink K, Feller A, Heinz R
    Blood. 1999 ; 94 (9) : 3114-3120.
    PMID 10556197
     
    Prognostic value of chromosomal abnormalities in follicular lymphoma.
    Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, Bastard C
    Blood. 1994 ; 84 (4) : 1043-1049.
    PMID 8049424
     
    Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin's lymphomas with BCL6/LAZ3 rearrangement.
    Wlodarska I, Mecucci C, Stul M, Michaux L, Pittaluga S, Hernandez JM, Cassiman JJ, De Wolf-Peeters C, Van den Berghe H
    Genes, chromosomes & cancer. 1995 ; 14 (1) : 1-7.
    PMID 8527378
     
    Identification and characterization of BCL6 translocation partner genes in primary gastric high-grade B-cell lymphoma: heat shock protein 89 alpha is a novel fusion partner gene of BCL6.
    Xu WS, Liang RH, Srivastava G
    Genes, chromosomes & cancer. 2000 ; 27 (1) : 69-75.
    PMID 10564588
     
    Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA - PCR analyses of biopsy samples.
    Yoshida S, Kaneita Y, Aoki Y, Seto M, Mori S, Moriyama M
    Oncogene. 1999 ; 18 (56) : 7994-7999.
    PMID 10637510
     

    Citation

    This paper should be referenced as such :
    Cuneo, A ; Huret, JL
    3q27 rearrangements in non Hodgkin lymphoma - t(3;Var)(q27;Var) in non Hodgkin lymphoma
    Atlas Genet Cytogenet Oncol Haematol. 2000;4(3):131-134.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Anomalies/3q27ID2081.html


    Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

    Genes BCL6

    External links

    arrayMap (UZH-SIB Zurich)
    arrayMap[select an item]
     
     
    Disease database3q27 rearrangements (BCL6) in non Hodgkin lymphoma
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed
    All articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Mon Sep 18 17:18:19 CEST 2017


    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.